
PTC Therapeutics Hits New 52-Week High of $69.88, Up 81.1%
2025-10-31 16:11:37PTC Therapeutics, Inc. achieved a new 52-week high of USD 69.88 on October 30, 2025, marking a significant increase from its low of USD 35.95. The company, with a market cap of USD 4,524 million, has shown strong performance over the past year, outpacing the S&P 500.
Read More
PTC Therapeutics Hits New 52-Week High of $69.26, Up 82.16%
2025-10-16 18:15:43PTC Therapeutics, Inc. achieved a new 52-week high of USD 69.26 on October 15, 2025, following a significant increase from its 52-week low of USD 35.51. The company, with a market cap of USD 4,524 million, has shown strong performance in the Pharmaceuticals & Biotechnology sector.
Read More
PTC Therapeutics, Inc. Hits New 52-Week High of $67.40
2025-10-06 17:31:21PTC Therapeutics, Inc. achieved a new 52-week high on October 3, 2025, reflecting strong performance in the pharmaceuticals and biotechnology sector. The company has seen a significant increase over the past year, with a market capitalization of USD 4,524 million and a low return on equity.
Read MoreIs PTC Therapeutics, Inc. technically bullish or bearish?
2025-09-20 19:47:40As of 2 September 2025, the technical trend for PTC Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate bullishness across both periods. Daily moving averages confirm a bullish trend as well. However, the weekly RSI is bearish, which suggests some caution. Dow Theory and OBV are both mildly bullish on a weekly and monthly basis. In terms of performance, PTC Therapeutics has significantly outperformed the S&P 500 across multiple periods, with a 1-month return of 26.27% compared to the S&P 500's 2.33%, and a 1-year return of 77.23% versus 17.14%....
Read More
PTC Therapeutics Hits New 52-Week High of $63.19, Up 67% Yearly
2025-09-19 13:00:19PTC Therapeutics, Inc. has achieved a new 52-week high, reflecting a substantial increase from its previous low. The company, with a market capitalization of USD 4,524 million, operates in the Pharmaceuticals & Biotechnology sector. Despite challenges in profitability and a high debt-to-equity ratio, its stock performance has notably outpaced the S&P 500.
Read More





